Cutaneous sarcoidosis due to immune‐checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor

Sarcoidosis is a non‐infective granulomatous disorder of unknown aetiology, with cutaneous involvement affecting up to 30% of patients. Drug‐induced sarcoidosis has been reported secondary to modern melanoma therapies including immune‐checkpoint inhibitors and first generation BRAF inhibitors such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, J. P., Star, P., Wong, S., Damian, D. L., Saw, R. P. M., Whitfeld, M. J., Menzies, A. M., Joshua, A. M., Smith, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060087/
https://www.ncbi.nlm.nih.gov/pubmed/35663773
http://dx.doi.org/10.1002/ski2.71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060087/
https://www.ncbi.nlm.nih.gov/pubmed/35663773
http://dx.doi.org/10.1002/ski2.71

Ejemplares similares